News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,183 Results
Type
Article (63452)
Company Profile (311)
Press Release (643420)
Section
Business (195606)
Career Advice (2851)
Deals (36181)
Drug Delivery (113)
Drug Development (83411)
Employer Resources (166)
FDA (16770)
Job Trends (15228)
News (341667)
Policy (34044)
Tag
Academia (2813)
Alliances (49133)
Alzheimer's disease (1291)
Approvals (16679)
Artificial intelligence (160)
Bankruptcy (327)
Best Places to Work (11837)
Biotechnology (229)
Breast cancer (146)
Cancer (1227)
Cardiovascular disease (111)
Career advice (2399)
Cell therapy (277)
Clinical research (66146)
Collaboration (438)
Compensation (198)
COVID-19 (2699)
C-suite (114)
Data (1200)
Diabetes (165)
Diagnostics (6477)
Earnings (71782)
Employer resources (148)
Events (107874)
Executive appointments (343)
FDA (17358)
Funding (388)
Gene therapy (207)
GLP-1 (640)
Government (4765)
Healthcare (19711)
Infectious disease (2787)
Inflammatory bowel disease (120)
Interviews (535)
IPO (16617)
Job creations (3799)
Job search strategy (2022)
Layoffs (476)
Legal (8166)
Lung cancer (193)
Manufacturing (201)
Medical device (13538)
Medtech (13543)
Mergers & acquisitions (19687)
Metabolic disorders (448)
Neuroscience (1600)
NextGen Class of 2024 (6921)
Non-profit (4745)
Northern California (1527)
Obesity (252)
Opinion (237)
Patents (117)
People (60105)
Phase I (20586)
Phase II (29007)
Phase III (21708)
Pipeline (484)
Postmarket research (2764)
Preclinical (8863)
Radiopharmaceuticals (258)
Rare diseases (254)
Real estate (6330)
Regulatory (22547)
Research institute (2520)
Resumes & cover letters (439)
Southern California (1331)
Startups (3633)
United States (14134)
Vaccines (616)
Weight loss (199)
Date
Today (114)
Last 7 days (401)
Last 30 days (3328)
Last 365 days (36459)
2024 (34234)
2023 (40792)
2022 (51970)
2021 (56812)
2020 (55460)
2019 (48581)
2018 (37010)
2017 (33918)
2016 (33363)
2015 (38972)
2014 (31910)
2013 (31028)
2012 (29413)
2011 (29695)
2010 (28032)
Location
Africa (955)
Arizona (160)
Asia (41973)
Australia (7368)
California (3445)
Canada (1301)
China (280)
Colorado (153)
Connecticut (170)
Europe (96657)
Florida (485)
Georgia (128)
Illinois (380)
Indiana (204)
Kansas (96)
Maryland (604)
Massachusetts (2780)
Michigan (166)
Minnesota (287)
New Jersey (1002)
New York (991)
North Carolina (796)
Northern California (1527)
Ohio (146)
Pennsylvania (839)
South America (1305)
Southern California (1331)
Texas (500)
Utah (94)
Washington State (377)
707,183 Results for "paragon gene therapy a unit of catalent biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of better treatments for patients worldwide, entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.
May 8, 2024
·
2 min read
Press Releases
Paragon Therapeutics Appoints Susanna High as Chief Executive Officer
November 21, 2024
·
3 min read
Pipeline
Neurogene Drops Batten Gene Therapy Program
After failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells investors that it’s evaluating options for the program.
November 19, 2024
·
2 min read
·
Kate Goodwin
Deals
Amid Novo Buy, Catalent Offloads New Jersey Facility to Ardena
European CDMO Ardena will buy Catalent’s oral solids manufacturing facility in Somerset, N.J.
October 14, 2024
·
1 min read
·
Annalee Armstrong
Duchenne muscular dystrophy
Regenxbio Gears Up to Challenge Sarepta in DMD as Gene Therapy Advances to Pivotal Studies
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for 2026—potentially posing a threat to Sarepta’s Elevidys.
November 19, 2024
·
2 min read
·
Tristan Manalac
Approvals
PTC Wins First FDA Nod for Direct-to-Brain Gene Therapy, Targets Ultrarare Disease
The FDA has followed in the footsteps of its European counterparts and granted accelerated approval to PTC Therapeutics’ gene therapy Kebilidi for AADC deficiency. It is the first approved gene therapy to be delivered directly to the brain.
November 14, 2024
·
2 min read
·
Tristan Manalac
Gene therapy
Neurogene Details Gene Therapy Complication, Sending Shares Plummeting Again
Neurogene’s shares fell by 36% as the market opened Monday morning following news that a patient experienced systemic hyperinflammatory syndrome in a Phase I/II clinical trial of Rett syndrome gene therapy NGN-401.
November 18, 2024
·
2 min read
·
Annalee Armstrong
Editorial
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo Nordisk Foundation, one of the world’s largest charitable foundations.
October 24, 2024
·
6 min read
·
Jef Akst
Editorial
Lilly vs. Novo: The ‘He Said, She Said’ Row About Catalent’s GLP-1 Work
With Novo Holdings’ $16.5 billion buyout of Catalent being reviewed by regulators, what work the contract drug manufacturer may or may not be performing for Eli Lilly remains a point of contention.
November 8, 2024
·
4 min read
·
Greg Slabodkin
Podcast
Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More
J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona comes at a bad time for the company; Sen. Warren calls for scrutiny of Novo’s purchase of Catalent; and other news.
October 16, 2024
·
1 min read
·
Heather McKenzie
1 of 70,719
Next
